Systematic review and meta-analysis of nitrates/nitrites in patients with heart failure or pulmonary hypertension
Related Experiment Video
Updated: Sep 14, 2025

Chemiluminescence-based Assays for Detection of Nitric Oxide and its Derivatives from Autoxidation and Nitrosated Compounds
Published on: February 16, 2022
Yujuan Huang1, Zhuojun Bai1, Li Wang1
1Department of Cardiovascular Medicine, Zhuzhou Hospital Affiliated to Xiangya School of Medicine, Central South University, No. 116 South Changjiang Road, Zhuzhou, 412007, Hunan, China.
Background:
Heart failure (HF) and pulmonary hypertension (PH) are prevalent cardiovascular diseases that often coexist and share common pathophysiological mechanisms, particularly dysregulation of nitric oxide metabolism, yet their clinical efficacy has been inconsistent.
Methods:
We systematically searched databases including PubMed, Web of Science, Embase, and the Cochrane Library for studies published over the past 15 years assessing nitrate/nitrite effects on cardiac function, hemodynamics, and exercise capacity in HF or PH patients. Data were analyzed using a random-effects model, with results as mean differences (MD) and 95% confidence intervals (CI). PROSPERO registration: CRD42024614911.
Results:
14 trials (n = 469) involving HF, PH, or pulmonary hypertension due to left heart disease (PH-LHD) were included. During exercise, nitrates significantly improved cardiac function in HF/PH-LHD patients, increasing stroke volume by 0.86 mL (95% CI 0.35 to 1.36; P < 0.05) and cardiac output by 0.57 L/min (95% CI 0.12 to 1.02; P < 0.05). At rest, nitrates reduced hemodynamic parameters in HF/PH patients: systolic blood pressure ,SBP (- 0.36 mmHg; 95% CI - 0.53 to - 0.18; P < 0.05), diastolic blood pressure, DBP (- 0.19 mmHg; 95% CI - 0.37 to - 0.01; P < 0.05), and right atrial pressure, RAP (- 0.70 mmHg; 95% CI - 1.35 to - 0.05; P < 0.05). These effects were attenuated during exercise. Neither administration methods, exercise intensity, nor ejection fraction significantly influenced hemodynamic improvements. Nitrates did not significantly improve oxygen consumption at rest (- 0.17 mL/min; 95% CI - 0.56 to 0.21; P = 0.65) or during exercise (0.25 mL/kg/min; 95% CI - 0.04 to 0.54; P = 0.10).
Conclusion:
Nitrate/nitrite therapy improves cardiopulmonary hemodynamics at rest and enhances cardiac function during exercise in HF and PH patients, though the drug-related benefits appear more limited. These hemodynamic improvements occur consistently regardless of exercise intensity or baseline ejection fraction. The dissociation between hemodynamic and functional measures suggests nitrate medications may be particularly valuable for addressing resting hemodynamic overload in this population.
Related Concept Videos
Antianginal Drugs: Nitrates and β-Blockers
Organic nitrates, such as nitroglycerin, play a pivotal role. Once metabolized, they liberate nitric oxide, a molecular marvel. Nitric oxide triggers guanylyl cyclase and augments cGMP production. This biochemical cascade orchestrates the relaxation of vascular smooth muscles, ushering in vasodilation and enhancing coronary blood flow....
Heart Failure Drugs: Inhibitors of Renin-Angiotensin System
Heart Failure V: Medical Management
Heart Failure Drugs: β-Blockers
Antihypertensive Drugs: Vasodilators
Angina V: Nursing Management

